

About Altoida
We’re pioneering precision neurology by building the world’s leading platform for reliable, accessible, affordable diagnosis and monitoring of neurological diseases.

Our Story
This drove me to engineer a virtual environment to assess the changes in brain health, both cognitive and functional, that I observed firsthand with my grandmother. I learned that exercises in a virtual environment open up an entirely new horizon of more meaningful measurements and data that can be acquired. From there, we spent 20 years of research to bring us to where we are today.”
- Ioannis Tarnanas, Ph.D. - Co-Founder and Chief Scientific Officer (CSO)
Our Growth
Early Scientific Research
Active digital biomarkers provide a new understanding of neurocognitive function.
First Validation Study
Five-year study on Altoida's simulation of ADL's to predict Alzheimer's conversions.
EIT Innovators Award
Dr. Tarnanas presents Altoida at TedX in Zurich; goes on to win EIT Innovators Award 2018.
Second Validation Study
Four-year study validating Altoida's 94% diagnostic accuracy for AD.
Nature Publication
Critical publication shows Altoida is the most sensitive measurement device.
FDA Breakthrough
Altoida's Breakthrough designation pioneers Precision Neurology.
Revolutionizing Brain Health
Discover Your Path to Better Brain Health
